246 related articles for article (PubMed ID: 23025511)
1. The CRTH2 antagonist OC000459 reduces nasal and ocular symptoms in allergic subjects exposed to grass pollen, a randomised, placebo-controlled, double-blind trial.
Horak F; Zieglmayer P; Zieglmayer R; Lemell P; Collins LP; Hunter MG; Steiner J; Lewis T; Payton MA; Perkins CM; Pettipher R
Allergy; 2012 Dec; 67(12):1572-9. PubMed ID: 23025511
[TBL] [Abstract][Full Text] [Related]
2. A randomized, double-blind, placebo-controlled study of the CRTH2 antagonist OC000459 in moderate persistent asthma.
Barnes N; Pavord I; Chuchalin A; Bell J; Hunter M; Lewis T; Parker D; Payton M; Collins LP; Pettipher R; Steiner J; Perkins CM
Clin Exp Allergy; 2012 Jan; 42(1):38-48. PubMed ID: 21762224
[TBL] [Abstract][Full Text] [Related]
3. Anti-eosinophil activity and clinical efficacy of the CRTH2 antagonist OC000459 in eosinophilic esophagitis.
Straumann A; Hoesli S; Bussmann Ch; Stuck M; Perkins M; Collins LP; Payton M; Pettipher R; Hunter M; Steiner J; Simon HU
Allergy; 2013 Mar; 68(3):375-85. PubMed ID: 23379537
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of the asthmatic allergen challenge response by the CRTH2 antagonist OC000459.
Singh D; Cadden P; Hunter M; Pearce Collins L; Perkins M; Pettipher R; Townsend E; Vinall S; O'Connor B
Eur Respir J; 2013 Jan; 41(1):46-52. PubMed ID: 22496329
[TBL] [Abstract][Full Text] [Related]
5. Efficacy of the oral chemoattractant receptor homologous molecule on TH2 cells antagonist BI 671800 in patients with seasonal allergic rhinitis.
Krug N; Gupta A; Badorrek P; Koenen R; Mueller M; Pivovarova A; Hilbert J; Wetzel K; Hohlfeld JM; Wood C
J Allergy Clin Immunol; 2014 Feb; 133(2):414-9. PubMed ID: 24332218
[TBL] [Abstract][Full Text] [Related]
6. Immunologic effect and tolerability of intra-seasonal subcutaneous immunotherapy with an 8-day up-dosing schedule to 10,000 standardized quality-units: a double-blind, randomized, placebo-controlled trial.
Pfaar O; Wolf H; Klimek L; Schnitker J; Wüstenberg E
Clin Ther; 2012 Oct; 34(10):2072-81. PubMed ID: 23063373
[TBL] [Abstract][Full Text] [Related]
7. Immunologic effects and tolerability profile of in-season initiation of a standardized-quality grass allergy immunotherapy tablet: a phase III, multicenter, randomized, double-blind, placebo-controlled trial in adults with grass pollen-induced rhinoconjunctivitis.
Reich K; Gessner C; Kroker A; Schwab JA; Pohl W; Villesen H; Wüstenberg E; Emminger W
Clin Ther; 2011 Jul; 33(7):828-40. PubMed ID: 21741092
[TBL] [Abstract][Full Text] [Related]
8. Heightened response of eosinophilic asthmatic patients to the CRTH2 antagonist OC000459.
Pettipher R; Hunter MG; Perkins CM; Collins LP; Lewis T; Baillet M; Steiner J; Bell J; Payton MA
Allergy; 2014 Sep; 69(9):1223-32. PubMed ID: 24866478
[TBL] [Abstract][Full Text] [Related]
9. Sublingual immunotherapy with a standardised grass pollen extract; a double-blind placebo-controlled study.
Hordijk GJ; Antvelink JB; Luwema RA
Allergol Immunopathol (Madr); 1998; 26(5):234-40. PubMed ID: 9885731
[TBL] [Abstract][Full Text] [Related]
10. Grass pollen immunotherapy as an effective therapy for childhood seasonal allergic asthma.
Roberts G; Hurley C; Turcanu V; Lack G
J Allergy Clin Immunol; 2006 Feb; 117(2):263-8. PubMed ID: 16461125
[TBL] [Abstract][Full Text] [Related]
11. Specific immunotherapy with SQ standardized grass allergen tablets in asthmatics with rhinoconjunctivitis.
Dahl R; Stender A; Rak S
Allergy; 2006 Feb; 61(2):185-90. PubMed ID: 16409194
[TBL] [Abstract][Full Text] [Related]
12. Sublingual immunotherapy with once-daily grass allergen tablets: a randomized controlled trial in seasonal allergic rhinoconjunctivitis.
Durham SR; Yang WH; Pedersen MR; Johansen N; Rak S
J Allergy Clin Immunol; 2006 Apr; 117(4):802-9. PubMed ID: 16630937
[TBL] [Abstract][Full Text] [Related]
13. High-dose sublingual immunotherapy with single-dose aqueous grass pollen extract in children is effective and safe: a double-blind, placebo-controlled study.
Wahn U; Klimek L; Ploszczuk A; Adelt T; Sandner B; Trebas-Pietras E; Eberle P; Bufe A;
J Allergy Clin Immunol; 2012 Oct; 130(4):886-93.e5. PubMed ID: 22939758
[TBL] [Abstract][Full Text] [Related]
14. Grass allergen tablet immunotherapy relieves individual seasonal eye and nasal symptoms, including nasal blockage.
Durham SR; Riis B
Allergy; 2007 Aug; 62(8):954-7. PubMed ID: 17620075
[TBL] [Abstract][Full Text] [Related]
15. Pharmacologic profile of OC000459, a potent, selective, and orally active D prostanoid receptor 2 antagonist that inhibits mast cell-dependent activation of T helper 2 lymphocytes and eosinophils.
Pettipher R; Vinall SL; Xue L; Speight G; Townsend ER; Gazi L; Whelan CJ; Armer RE; Payton MA; Hunter MG
J Pharmacol Exp Ther; 2012 Feb; 340(2):473-82. PubMed ID: 22106101
[TBL] [Abstract][Full Text] [Related]
16. Nasal corticosteroid treatment reduces substance P levels in tear fluid in allergic rhinoconjunctivitis.
Callebaut I; Vandewalle E; Hox V; Bobic S; Jorissen M; Stalmans I; De Vries A; Scadding G; Hellings PW
Ann Allergy Asthma Immunol; 2012 Aug; 109(2):141-6. PubMed ID: 22840257
[TBL] [Abstract][Full Text] [Related]
17. Sustained 3-year efficacy of pre- and coseasonal 5-grass-pollen sublingual immunotherapy tablets in patients with grass pollen-induced rhinoconjunctivitis.
Didier A; Worm M; Horak F; Sussman G; de Beaumont O; Le Gall M; Melac M; Malling HJ
J Allergy Clin Immunol; 2011 Sep; 128(3):559-66. PubMed ID: 21802126
[TBL] [Abstract][Full Text] [Related]
18. Efficacy of sublingual swallow immunotherapy in children with severe grass pollen allergic symptoms: a double-blind placebo-controlled study.
Bufe A; Ziegler-Kirbach E; Stoeckmann E; Heidemann P; Gehlhar K; Holland-Letz T; Braun W
Allergy; 2004 May; 59(5):498-504. PubMed ID: 15080830
[TBL] [Abstract][Full Text] [Related]
19. Comparative effect of pre-coseasonal and continuous grass sublingual immunotherapy in children.
Stelmach I; Kaluzińska-Parzyszek I; Jerzynska J; Stelmach P; Stelmach W; Majak P
Allergy; 2012 Mar; 67(3):312-20. PubMed ID: 22142341
[TBL] [Abstract][Full Text] [Related]
20. Desloratadine reduces systemic allergic inflammation following nasal provocation in allergic rhinitis and asthma patients.
Reinartz SM; Overbeek SE; Kleinjan A; van Drunen CM; Braunstahl GJ; Hoogsteden HC; Fokkens WJ
Allergy; 2005 Oct; 60(10):1301-7. PubMed ID: 16134997
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
